Lercanidipina Tecnigen

Lercanidipine hydrochloride, the active ingredient in Lercanidipina Tecnigen, is a calcium channel blocker presented as a tablet for oral use. It is employed to lower elevated blood pressure in adult patients diagnosed with hypertension. The medication is formulated for once‑daily administration, delivering sustained vasodilation by selectively inhibiting L‑type calcium channels in vascular smooth muscle, which helps maintain consistent blood‑pressure control throughout the day.

GNH USA supplies Lercanidipina Tecnigen as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring quality‑assured bulk shipments and regulatory compliance.

Lercanidipine is a calcium channel blocker indicated for the management of hypertension, a condition characterized by chronically elevated arterial pressure that increases the risk of heart attack, stroke, and kidney disease.

Hypertension: reduces systolic and diastolic blood pressure, helping to achieve target levels and lower cardiovascular risk. Essential hypertension: provides consistent blood‑pressure reduction, improving long‑term cardiovascular outcomes. Isolated systolic hypertension: effectively lowers systolic pressure, which is predominant in older adults. Adjunct therapy: can be combined with other antihypertensives to achieve target blood pressure when monotherapy is insufficient.

Lercanidipine may be associated with several adverse reactions, which are classified by frequency and severity.

Common Side Effects: - Headache: mild to moderate headache occurring early in therapy. - Flushing: transient warmth and redness of the skin. - Peripheral edema: swelling of ankles or lower legs. - Dizziness: sensation of light‑headedness, especially after standing. - Tachycardia: increased heart rate without other cause.

Serious or Rare Side Effects: - Severe hypotension: marked drop in blood pressure leading to fainting. - Angioedema: swelling of face, lips, tongue or airway requiring urgent care. - Hepatic dysfunction: abnormal liver enzymes or hepatitis.

When prescribing lercanidipine, clinicians should consider several precautionary measures to ensure safe use.

Blood pressure monitoring: check baseline and periodic readings to assess efficacy. Concomitant antihypertensives: adjust dose when used with other agents that lower blood pressure. Hepatic impairment: use with caution in patients with liver dysfunction, as metabolism may be reduced. Pregnancy and lactation: avoid use during pregnancy and breastfeeding due to unknown safety. Drug interactions: review patient’s medication list for CYP3A4 inhibitors or inducers. Store below 25°C: keep tablets in the original container, protect from moisture and light.

Lercanidipine can interact with other medicines, altering its antihypertensive effect or increasing adverse reactions.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may raise plasma levels, risking toxicity. - Grapefruit juice: can increase drug exposure leading to excessive hypotension. - Other potent vasodilators: combined use may cause severe hypotension.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce effectiveness. - Diuretics: may enhance blood‑pressure lowering effect, requiring dose adjustment. - NSAIDs: can attenuate antihypertensive response.